CARG-2020 a novel immunemodulatory approach to prevent recurrent ovarian cancer.

被引：0
|
作者：
Alvero, Ayesha B. [1 ]
Fox, Alexandra [1 ]
Madina, Bhaskara [2 ]
Krady, Marie [2 ]
Yarovinski, Timur O. [2 ]
Nakaar, Valerian [2 ]
Almassian, Bijan [2 ]
Mor, Gil [1 ]
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] Carogen, Farmington, CT USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5370
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] NOVEL CASE OF TRANSVAGINAL OOCYTE RETRIEVAL FOLLOWING OVARIAN TRANSPOSITION AND REVERSAL IN A PATIENT WITH RECURRENT RECTAL CANCER.
    Thanh Ha Luu
    Lersten, Ivy L.
    Foust, Erin H.
    Polotsky, Alex J.
    Alldredge, Jill
    Appiah, Leslie Coker
    FERTILITY AND STERILITY, 2021, 116 (03) : E217 - E218
  • [23] SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer
    Wang, Yinu
    Cardenas, Horacio
    Fang, Fang
    Condello, Salvatore
    Taverna, Pietro
    Choy, Gavin
    Azab, Mohammad
    Nephew, Kenneth
    Matei, Daniela
    CANCER RESEARCH, 2014, 74 (19)
  • [24] Novel Role of Titin in the Development of Chemoresistance in Ovarian Cancer.
    Harper, Amy K.
    Fletcher, Nicole M.
    Fan, Rong
    Morris, Robert
    Saed, Ghassan M.
    REPRODUCTIVE SCIENCES, 2019, 26 : 159A - 159A
  • [25] A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
    Ling, Huichung Tina
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Direct comparison of PET and PET/CT in the detection of recurrent ovarian cancer.
    Cohade, C
    Mourtzikos, KA
    Pannu, HK
    Leal, JP
    Bristow, RE
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 129P - 130P
  • [27] Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer.
    O'Cearbhaill, Roisin Eilish
    Hyman, David Michael
    Tew, William P.
    Iasonos, Alexia
    Cangemi, Nicholas A.
    Aghajanian, Carol
    Bell-McGuinn, Katherine M.
    Makker, Vicky
    Hensley, Martee Leigh
    Konner, Jason A.
    Grisham, Rachel N.
    Diaz-Macinnis, Katherine
    Sabbatini, Paul
    Spriggs, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] A study of weekly Taxol® in patients with recurrent platinum resistant ovarian cancer.
    Kaern, J
    Tropé, C
    Baekelandt, M
    Kristensen, GB
    Gundersen, G
    ANNALS OF ONCOLOGY, 2000, 11 : 85 - 85
  • [29] Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part II
    Wilczynski, Jacek R.
    Makula, Beata
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2011, 10 (05): : 363 - 367
  • [30] Evaluation of the role of premetrexed in the treatment of refractory, recurrent epithelial ovarian cancer.
    Kesterson, J. P.
    Kanis, M.
    Lele, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345